Keywords: Gaucher disease, Genzyme Corp, Shire, enzyme replacement therapy

Genzyme's problems continue as Shire comes up with new Gaucher drug

Article | 10 August 2009

Print This

According to analysts at Zacks Investment Research, US biotechnology major Genzyme Corp suffered a setback earlier this week when UK-based ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in